RAS-Selective PI3Kα Inhibitor
RAS-mutant solid tumors
Preclinical / Early ClinicalDiscovery/Lead Optimization
Key Facts
Indication
RAS-mutant solid tumors
Phase
Preclinical / Early Clinical
Status
Discovery/Lead Optimization
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics (BBOT) is a focused, public subsidiary of BridgeBio Pharma, established to conquer RAS-driven cancers through a novel, dual-pathway inhibition strategy. The company's mission is to translate deep biological insights into therapies that directly inhibit the active, GTP-bound state of RAS mutants and the PI3Kα pathway, a key resistance mechanism. Its strategy leverages the operational and financial infrastructure of its parent company to advance a targeted pipeline aimed at significant markets in pancreatic, colorectal, and lung cancers. While still in early clinical stages, BBOT represents a scientifically rigorous contender in the rapidly evolving post-KRAS G12C inhibitor landscape.
View full company profile